Type 1 and type 2 diabetes, insulin resistance, glucose metabolism, and metabolic health
290 articles
A 745-person genomic study identifies why metformin concentrations vary so widely — with ancestry-specific genetic variants playing a key role.
A randomized trial shows that extending overnight fasting by 3 hours, timed to sleep, cuts nighttime heart rate and improves glucose control.
A major review repositions type 2 diabetes as a proteinopathy, with amylin aggregation bridging metabolic decline and neurodegeneration.
A 16-week RCT finds metformin blocks exercise-induced improvements in artery and capillary function in adults at metabolic syndrome risk.
New sensor data shows type 1 diabetics on ketogenic diets experience frequent, short-lived, asymptomatic ketosis episodes — mostly harmless.
A new review maps how tirzepatide's dual GIP/GLP-1 action reshapes metabolism across the pancreas, liver, gut, heart, kidneys, and brain.
People with schizophrenia exposed to the most nighttime light face 4x higher obesity odds and 3x higher hypertension odds.
A 5-year cohort study finds that CGM-derived time in range predicts arterial stiffness changes independently of HbA1c in type 2 diabetes.
A 10-year Korean cohort study finds GLP-1 receptor agonists don't raise psychiatric risk compared to DPP-4 inhibitors, but show modest signals vs SGLT2 inhibitors.
A traditional Chinese formula and its key compound GsRg1 restore brain insulin signaling in obese rats by activating hypothalamic self-cleaning pathways.
A 30-week Pakistani multicentre study shows biosynthetic semaglutide delivers clinically meaningful glycemic and weight benefits in routine care.
Aging adipose tissue loses its ability to generate new fat cells, driving insulin resistance. New review maps the molecular culprits and best treatment options.
